Navigation Links
$89 Million Proposed Class Action Settlement Provides Consumers and Insurers With Money Back for Celebrex and Bextra Purchases and Reimbursements
Date:4/29/2009

WASHINGTON, April 29 /PRNewswire-USNewswire/ -- A federal court in San Francisco has granted preliminary approval to a proposed settlement with Pfizer Inc. ("Pfizer") about the marketing of the prescription drugs Bextra and Celebrex. The settlement in the case called In re Bextra and Celebrex Marketing, Sales Practices, and Product Liability Litigation, No. 05-CV-01669, MDL No. 1699, pending in the United States District Court for the Northern District of California, will provide a Settlement Fund of $89 million to benefit a class of consumers and insurance companies or other entities (also called Third-Party Payors) that paid for either medicine before July 29, 2005.

The lawsuit, which does not concern safety risk of either drug, claims that Pfizer falsely advertised Bextra and Celebrex as having greater benefits than less expensive pain medications, causing consumers and other entities to pay a greater price for Bextra and Celebrex than they would otherwise have paid for less expensive alternatives or no medications at all. The lawsuit also claims that the advertising was not consistent with the drugs' Food and Drug Administration approved labeling. Pfizer denies any wrongdoing and denies all of the claims in the lawsuit but is settling this lawsuit to avoid the cost and expense of further litigation.

Consumers who paid for Bextra and/or Celebrex on or before July 29, 2005 are included in the Proposed Settlement. Third-Party Payors that paid or reimbursed for all or a percentage of the cost of Bextra and/or Celebrex on or before July 29, 2005 can also make a recovery under the Proposed Settlement. Third-Party Payors include insurance companies, union health and welfare plans, and self-insured employers.

Consumers and Third-Party Payors that wish to remain in the Settlement and file a claim will be bound by the Court's orders and will give up the right to sue the defendants on their own. Claim forms must be postmarked by October 23, 2009.

The Court will hold a Final Approval Hearing on September 25, 2009 at 10 a.m. to consider whether the Proposed Settlement is fair, reasonable, and adequate and the motion for attorneys' fees and expenses. For more information, including a claim form, Class Members may call toll-free 1-800-547-9360, visit www.BextraCelebrexSettlement.com, or write: Bextra and Celebrex Claims Administrator, c/o Rust Consulting, Inc., P.O. Box 24675, West Palm Beach, FL 33416.


'/>"/>
SOURCE Bextra and Celebrex Claims Administrator
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Registered Organ Donors Near Five Million, Save 300 Lives Since 2006
2. Kaiser Permanente Approves $13 Million in Community Benefit Grants in First Quarter of 2009
3. FSU researcher wins $2.2 million grant to study childhood obesity
4. UN Foundation to Help Protect More than a Million Refugees from Malaria in Africa
5. Treatment Options Increase For Millions with Fibromyalgia
6. Attorney General Eric Holder Honors Florida Doctor and Announces $4.7 Million in Recovery Act Funds for State
7. Neovasc Completes $2 Million Non-Brokered Private Placement
8. Working Towards Counting Malaria Out Through Scale-Up of PermaNet(R) Bed Nets, Vestergaard Frandsen Produces 175 Millionth Net; Introduces New Net To Combat Insecticide Resistance
9. Millions of Youth Around the World Volunteer to Improve Communities
10. Proposed $350 Million Class Action Settlement Regarding Drug Pricing Provides Consumers and Third-Party Payors With Money Back
11. The Female Health Company / HLL Lifecare Limited Receive National AIDS Control Organization of India Order for 1.5 Million FC2 Female Condoms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/24/2017)... ... , ... There is no doubt in anyone’s mind that NoSQL databases scale out to large ... the ability to scale to a 1000 nodes, Gensonix can scale to 100,000 nodes without ... Big Data loads. , First of all, Gensonix stands as the only DB (SQL or ...
(Date:8/24/2017)... Fredericton, NB (PRWEB) , ... August 24, 2017 , ... ... culmination of 18 years of contact center application development experience. It represents ... modern contact center. , Indosoft designed Q-Suite NG for simple integration. A full ...
(Date:8/23/2017)... , ... August 23, 2017 , ... The Arc Mercer, ... disabilities (I/DD), has launched a groundbreaking LGBTQ community organization for people with special needs. ... organization of its kind in the state of New Jersey – but the first ...
(Date:8/23/2017)... , ... August 23, 2017 , ... ... Vice President Business Development and Sector Growth. Mr. Smith joins other recent high-profile ... , Mr. Smith’s healthcare career began in 1993, helping physician practices and ...
(Date:8/23/2017)... ... August 23, 2017 , ... Based on worldwide research and ... of HBOT in treating and helping to heal addictions and substance abuse disorders. ... similarities of the wounds to the brain from traumatic brain injuries, and the ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... , Aug. 7, 2017 Insightin ... member acquisition, retention, and engagement, announced the selection ... Strategy and Product Development, effective as of February 2017. ... and technology implementation strategy for our clients. Wood ... experience in consulting and business analytics within the ...
(Date:8/7/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent specialty ... 2017.  All comparisons, unless otherwise noted, are to the quarter ... Second Quarter 2017 Highlights include: ... of 3.5% Total prescriptions dispensed of 220,000, ... versus 7.6% Gross profit per prescription ...
(Date:8/4/2017)...  Agragen, LLC, a Cincinnati ... nutraceutical, and aquacultural feed sectors, announces a significant ... candidates, AGR131.  This drug is designed to trap ... of patients suffering from inflammatory conditions such as ... Biological pharmaceuticals currently ...
Breaking Medicine Technology: